An experimental vaccine could offer fresh hope to women diagnosed with an aggressive and hard-to-treat form of breast cancer, ...
The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...
A small clinical trial shows promising results for patients with triple-negative breast cancer who received an ...
Breast cancer patients have been given fresh hope after a new vaccine showed "promise" in treating an aggressive form of the ...
A small clinical trial shows promising results for patients with triple-negative breast cancer who received an investigational vaccine designed to prevent recurrence of tumors.
BioNTech, the German developer of a widely used mRNA vaccine for the coronavirus, agreed to pay US$800 million (HK$6.24 ...
University of Zagreb researcher Beata Halassy treated her breast cancer with an unproven virus-based therapy using viruses ...
Over the summer, BioNTech released Phase 2 data on its mRNA cancer vaccine in the works alongside Regeneron. The vaccine, ...
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...
The acquisition was part of BioNTech's broader oncology strategy, backed by the financial success of its Covid-19 vaccine ...
BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...